| Assessment Status |
23/06/2023 Submission withdrawn – Awaiting re-submission |
| HTA ID |
22032 |
| Drug |
Selumetinib |
| Brand |
Koselugo® |
| Indication |
For the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above. |
| Rapid review commissioned |
10/05/2022 |
| Rapid review completed |
25/05/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of selumetinib (Koselugo®) compared with the current standard-of-care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/07/2022 |
| Pre-submission consultation with Applicant |
20/09/2022 |
| Full submission received from Applicant |
09/01/2023 |
| Preliminary review sent to Applicant |
11/05/2023 |
